Triglyceride-glucose index on risk of adverse events after drug-coated balloon angioplasty
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Triglyceride-glucose index on risk of adverse events after drug-coated balloon angioplasty ; volume:22 ; number:1 ; day:28 ; month:10 ; year:2023 ; pages:1-11 ; date:12.2023
Lipids in health and disease ; 22, Heft 1 (28.10.2023), 1-11, 12.2023
- Classification
-
Medizin, Gesundheit
- Creator
-
Lin, Zhaorong
He, Xi
Lin, Maosen
Chen, Lianglong
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12944-023-01951-8
- URN
-
urn:nbn:de:101:1-2024011608265636964836
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lin, Zhaorong
- He, Xi
- Lin, Maosen
- Chen, Lianglong
- SpringerLink (Online service)
Other Objects (12)
Impact of Chocolate percutaneous transluminal angioplasty balloon on vessel preparation in drug-coated balloon angioplasty for femoropopliteal lesion
Investigating Balloon-Vessel Contact Pressure Patterns in Angioplasty: In Silico Insights for Drug-Coated Balloons
Systematic Scoring Balloon Lesion Preparation for Drug-Coated Balloon Angioplasty in Clinical Routine: Results of the PASSWORD Observational Study
Repeat drug-coated balloon angioplasty for femoropopliteal lesions: 12-month results from a retrospective observational study
Three-year sustained clinical efficacy of drug-coated balloon angioplasty in a real-world femoropopliteal cohort
Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practice
Rotarex®S rotational atherectomy combined with drug-coated balloon angioplasty for treating femoropopliteal artery in-stent restenosis
Association of non-insulin-dependent insulin resistance indices with lower limb artery restenosis after drug-coated balloon angioplasty
24-Month Registry Results on Drug-Coated Balloon Angioplasty Below the Knee: Strong Enough Evidence to Convince the Sceptics?
Dialysis Access Maintenance: Plain Balloon Angioplasty
Optimized drug‐coated balloon angioplasty of the superficial femoral and proximal popliteal arteries using the Tack Endovascular System: Tack Optimized Balloon Angioplasty (TOBA) III 24‐month results in standard and long lesions
Multivariable Regression Analysis of Clinical Data from the Randomized-Controlled EffPac Trial: Efficacy of Femoropopliteal Drug-Coated Balloon Angioplasty
Impact of Chocolate percutaneous transluminal angioplasty balloon on vessel preparation in drug-coated balloon angioplasty for femoropopliteal lesion
Investigating Balloon-Vessel Contact Pressure Patterns in Angioplasty: In Silico Insights for Drug-Coated Balloons
Systematic Scoring Balloon Lesion Preparation for Drug-Coated Balloon Angioplasty in Clinical Routine: Results of the PASSWORD Observational Study
Repeat drug-coated balloon angioplasty for femoropopliteal lesions: 12-month results from a retrospective observational study
Three-year sustained clinical efficacy of drug-coated balloon angioplasty in a real-world femoropopliteal cohort
Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practice
Rotarex®S rotational atherectomy combined with drug-coated balloon angioplasty for treating femoropopliteal artery in-stent restenosis
Association of non-insulin-dependent insulin resistance indices with lower limb artery restenosis after drug-coated balloon angioplasty
24-Month Registry Results on Drug-Coated Balloon Angioplasty Below the Knee: Strong Enough Evidence to Convince the Sceptics?
Dialysis Access Maintenance: Plain Balloon Angioplasty
Optimized drug‐coated balloon angioplasty of the superficial femoral and proximal popliteal arteries using the Tack Endovascular System: Tack Optimized Balloon Angioplasty (TOBA) III 24‐month results in standard and long lesions
Multivariable Regression Analysis of Clinical Data from the Randomized-Controlled EffPac Trial: Efficacy of Femoropopliteal Drug-Coated Balloon Angioplasty
Impact of Chocolate percutaneous transluminal angioplasty balloon on vessel preparation in drug-coated balloon angioplasty for femoropopliteal lesion
Investigating Balloon-Vessel Contact Pressure Patterns in Angioplasty: In Silico Insights for Drug-Coated Balloons
Systematic Scoring Balloon Lesion Preparation for Drug-Coated Balloon Angioplasty in Clinical Routine: Results of the PASSWORD Observational Study
Repeat drug-coated balloon angioplasty for femoropopliteal lesions: 12-month results from a retrospective observational study
Three-year sustained clinical efficacy of drug-coated balloon angioplasty in a real-world femoropopliteal cohort
Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practice
Rotarex®S rotational atherectomy combined with drug-coated balloon angioplasty for treating femoropopliteal artery in-stent restenosis
Association of non-insulin-dependent insulin resistance indices with lower limb artery restenosis after drug-coated balloon angioplasty
24-Month Registry Results on Drug-Coated Balloon Angioplasty Below the Knee: Strong Enough Evidence to Convince the Sceptics?
Dialysis Access Maintenance: Plain Balloon Angioplasty
Optimized drug‐coated balloon angioplasty of the superficial femoral and proximal popliteal arteries using the Tack Endovascular System: Tack Optimized Balloon Angioplasty (TOBA) III 24‐month results in standard and long lesions